Hints and tips:
Related Special Reports
...University of Oxford spinout is pushing genetic testing beyond the search for individual genes, looking at how combinations of genes increase people’s likelihood of developing diseases such as cancer or cardiovascular...
...Trial results published in November showed that Wegovy led to an 18 per cent decline in risk of death for patients with obesity and cardiovascular disease....
...Some users of Medicare, the US government-funded insurance programme for seniors, will be able to access weight-loss drugs if they suffer from certain conditions such as cardiovascular disease, officials...
...First, they could start serious health spending on prevention (adult vaccines, cardiovascular disease, preventing the second fracture, fixing the antimicrobial resistance crisis would be great starts) as...
...Novo Nordisk, the maker of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, said the deal was an “important step” in its strategy to “establish a presence in cardiovascular disease”....
...Joaquin Duato, J&J’s chief executive, said the acquisition “provides a unique opportunity to accelerate our impact in cardiovascular intervention”....
...The company shared the trial results at a capital markets day for investors, where it outlined plans to tackle cardiovascular diseases and address supply constraints to meet high demand....
...A new study by Novo Nordisk has shown that its blockbuster drug Ozempic cut the risk of death, disease progression and cardiovascular issues by 24 per cent for patients with type 2 diabetes and chronic kidney...
...Referring to ‘immunosuppression’ and cardiovascular disorders, outline the role of stress in illness. What might have been ‘sources of stress’ for Angehrn?...
...Last month, Wegovy received FDA approval to help reduce heart attack and stroke risk in patients with cardiovascular disease, enabling it to be covered by insurance for the more than 50mn Americans on Medicare...
...J&J chief executive Joaquin Duato said the acquisition provided “a unique opportunity to accelerate our impact in cardiovascular intervention and drive greater value for patients, shareholders and health...
...Soriot took a very broad portfolio and focused on some of the newest areas of science, including oncology, rare diseases, cardiovascular, renal and metabolism (CVRM) and respiratory and immunology (R&I)....
...Novo Nordisk’s trial studied more than 17,600 people aged above 45 with obesity who had cardiovascular disease, but not diabetes....
...A Novo Nordisk trial published in November studied more than 17,600 people aged above 45 with obesity who had cardiovascular disease, but not diabetes, comparing Wegovy with a placebo....
...Novo Nordisk is trialling GLP-1 treatments on conditions including cardiovascular diseases and Alzheimer’s, but the lixisenatide trial is one of the first longer studies to suggest that a GLP-1 drug may...
...This scaly superfood is packed with micronutrients including omega-3 fatty acids (known to reduce the risk of cardiovascular disease and stroke), vitamins B12 and D, selenium and iron....
...Dropping the 70 per cent discount is a boon for makers of cheaper drugs, such as cardiovascular medications....
...Investors are excited not merely by the drugs’ effectiveness in tackling obesity, but also by their potential in reducing the impact of cardiovascular, liver and other diseases....
...Novo Nordisk’s obesity drug cuts the risk of major cardiovascular events such as heart attacks or strokes by 20 per cent compared with a placebo, bolstering the Danish drugmaker’s case that health systems...
...Novo Nordisk is also backing Cellarity, which is using artificial intelligence to develop treatments for MASH, a chronic liver disease that increases the risk of developing type-2 diabetes and cardiovascular...
...Nearly 10mn people a year die from cancer, a figure that is expected to rise, making it the second-biggest killer after cardiovascular disease....
...Even so, air pollution increases the risk of both respiratory and cardiovascular disease, and the global number of deaths caused by air pollution is estimated by both the World Health Organization and the...
...So far 50mn Americans have insurance coverage for Wegovy and last month the FDA approved its use to cut cardiovascular risks in obese and overweight patients....
...“In North America and in western Europe, there has been for 50 years now an enormous emphasis on preventing cardiovascular diseases . . . that led to heart attacks and strokes,” he says....
...McKinsey sees sales growth for overall medtech at well above pre-pandemic rates, with digital healthcare, cardiovascular health and robotics heading the list....
International Edition